Ascil Biopharm

A CDMO fully equipped for early-stage drug product development, with a GMP facility for clinical batches supporting aseptic processing and terminal sterilization across containers including vials and syringes, alongside formulation, device and analytical development capabilities. ASCIL's expertise spans a wide range of molecules, with particular focus on peptides and biologics — including proteins, fusion proteins, toxins and monoclonal antibodies — working on both its own and external assets across endocrine, cancer, infectious, dermatological and ocular disease areas.